Search

Additional file 1. Carers’ Experience of Assistive Technology use in dementia - Participant Information Sheet.

Additional file 3. Carers’ Experience of Assistive Technology use in dementia – Explanatory interviews: Interview topic guide.

Additional file 2. Carers’ Experience of Assistive Technology use in dementia - Participant Consent Form.

Supplemental material, sj-docx-3-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness

Supplemental material, sj-docx-3-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness

Additional file 1.

Supplemental material, sj-docx-1-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness

Supplemental material, sj-docx-2-chi-10.1177_17423953211060253 for Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness

MEDLINE (OVID) search strategy for this review. (DOCX 13 kb)

Data extraction forms. (DOCX 15 kb)

Table of inclusion and exclusion criteria for this review. (DOCX 15 kb)

Search strategy. (DOCX 18 kb)

Data from included studies. (DOCX 114 kb)

PRISMA-P checklist. (DOCX 35 kb)

Data extraction form for this review. (DOCX 15 kb)

PRISMA checklist. (DOCX 27 kb)

Background: The prevalence of type 2 diabetes is rising, placing increasing strain on health care services. Web-based and mobile technologies can be an important source of information and support for people with type 2 diabetes and may prove beneficial with respect to reducing complications due to mismanagement. To date, little research has been performed to gain an insight into people’s perspectives of using such technologies in their daily management. Objective: The purpose of this study was to understand the impact of using Web-based and mobile technologies to support the management of type 2 diabetes. Methods: In-depth interviews were conducted with 15 people with type 2 diabetes to explore experiences of using Web-based and mobile technologies to manage their diabetes. Transcripts were analyzed using the framework method. Results: Technology supported the users to maintain individualized and tailored goals when managing their health. A total of 7 themes were identified as important to participants when using technology to support self-management: (1) information, (2) understanding individual health and personal data, (3) reaching and sustaining goals, (4) minimizing disruption to daily life, (5) reassurance, (6) communicating with health care professionals, and (7) coordinated care. Conclusions: Patients need to be supported to manage their condition to improve well-being and prevent diabetes-related complications from arising. Technologies enabled the users to get an in-depth sense of how their body reacted to both lifestyle and medication factors—something that was much more difficult with the use of traditional standardized information alone. It is intended that the results of this study will inform a new questionnaire designed to assess self-management in people using Web-based and mobile technology to manage their health.

Supplementary material for Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level. Table S1. Overview of correlations between OKS outcome variables and covariates used in imputation models. Table S2. Overview of correlations between EQ-5D-3L outcome variables and covariates used in imputation models. Table S3. Overview of correlations between SF-12 outcome variables and covariates used in imputation models. Figures S1-S9. Supplementary graphs to Figs. 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 in the manuscript, showing mean absolute errors instead of root mean square errors. (DOCX 1613 kb)

Floor and ceiling effects for OxCAP-MH items scored on a 1 to 5 Likert scale. (DOCX 13Â kb)

Correlation of individual items of the OxCAP-MH with established measures of illness severity, functioning and social outcomes. (DOCX 13Â kb)

Peer reviewed: True, Funder: National Institute for Health Research (NIHR) Research for Patient Benefit (RfPB); Grant(s): Grant Reference Number: PB-PG-0815-20048, OBJECTIVE: A qualitative sub-study was carried out within a larger phase II feasibility trial, to identify and describe the burden experienced by advanced melanoma patients participating in a clinical trial and the factors affecting their capacity to cope with the burden. METHODS: Semi-structured interviews were conducted with fourteen patients with advanced melanoma recruited from National Health Service hospitals in the United Kingdom. Qualitative analysis was undertaken using a framework analysis approach. Normalisation process theory was applied to the concept of research participation burden in order to interpret and categorise findings. RESULTS: Burdens of participation were identified as arising from making sense of the trial and treatment; arranging transport, appointment and prescriptions; enacting management strategies and enduring side effects; reflecting on trial documents and treatment efficacy, and emotional and mental effects of randomisation and treatment side effects. Factors reported as influencing capacity include personal attributes and skills, physical and cognitive abilities and support network. DISCUSSION: This is the first study to highlight the substantial burden faced by patients with advanced melanoma in a clinical trial and factors that may lessen or worsen the burden. Consideration of identified burdens during trial design and execution will reduce the burden experienced by research participants.